• 1
    Craig JR, Peters RL, Edmondson HA. Tumors of the liver and intrahepatic bile ducts. Atlas of tumor pathology, 2nd series, fascicle 26. Washington DC: Armed Forces Institute of Pathology, 1989:
  • 2
    Hainsworth JD, Greco FA. Treatment of patients with cancer of unknown primary site. N Engl J Med 1993; 329:25763.
  • 3
    Nadji M, Tabei SZ, Castro A, Chu TM, Morales AR. Prostatic origin of tumours: an immunohistochemical study. Am J Clin Pathol 1980; 73:7359.
  • 4
    De Micco C, Ruf J, Carayon P, Chrestian MA, Henry JF, Toga M. Immunohistochemical study of thyroglobulin in thyroid carcinomas with monoclonal antibodies. Cancer 1987; 59:4716.
  • 5
    Fenoglio CM, Crum CP, Pascal RR, Richart RM. Carcinoembryonic antigen in gynecologic patients. Diagn Gynecol Obstet 1981; 3:2919.
  • 6
    Brown RW, Campagna LB, Dunn JK, Cagle PT. Immunohistochemical identification of tumor markers in metastatic adenocarcinoma. A diagnostic adjunct in the determination of primary site. Am J Clin Pathol 1997; 107:129.
  • 7
    Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982; 31:1124.
  • 8
    Moll R. Molecular diversity of cytokeratins: significance for cell and tumor differentiation. Acta Histochemica 1992; XLI(Suppl): 11727.
  • 9
    Czernobilsky B, Moll R, Franke WW, Dallenbach-Hellweg G, Hohlweg-Majert P. Intermediate filaments of normal and neoplastic tissues of the female genital tract with emphasis on problems of different tumor diagnosis. Pathol Res Pract 1984; 179:317.
  • 10
    Moll R, Löwe A, Laufer J, Franke WW. Cytokeratin 20 in human carcinomas. Am J Pathol 1992; 140:42747.
  • 11
    Ramaekers FCS, van Niekerk CC, Poels LG. Use of monoclonal antibodies to keratin 7 in the differential diagnosis of adenocarcinomas. Am J Pathol 1990; 136:64155.
  • 12
    Wauters CCAP, Smedts F, Gerrits LGM, Bosman MT, Ramaekers FC. Keratin 7 and 20 as diagnostic markers of carcinomas metastatic to the ovary. Hum Pathol 1995; 26:8525.
  • 13
    Loy TS, Calaluce RD. Utility of cytokeratin immunostaining in separating pulmonary adenocarcinomas from colonic adenocarcinomas. Am J Clin Pathol 1994; 102(6):7647.
  • 14
    Loy TS, Calaluce RD, Keeney GL. Cytokeratin immunostaining in differentiating primary ovarian carcinoma from metastatic colonic adenocarcinoma. Mod Pathol 1996; 9(11): 10404.
  • 15
    Berezowski K, Stastny JF, Kornstein MJ. Cytokeratin 7 and 20 and carcinoembryonic antigen in ovarian and colonic carcinoma. Mod Pathol 1996; 9(4): 4269
  • 16
    Sack JM, Roberts SA. Cytokeratin 20 and 7 in the differential diagnosis of metastatic carcinoma in cytologic specimens. Diagn Cytopathol 1997; 16(2):1326.
  • 17
    Moll R, Schiller DL, Franke WW. Identification of protein IT of the intestinal cytoskeleton as a novel type I cytokeratin with unusual properties and expression patterns. J Cell Biol 1990; 111:56780.
  • 18
    Ascoli V. Taccogna S. Scalzo CC, Nardi F. Utility of cytokeratin 20 in identifying the origin of metastatic carcinomas in effusions. Diagn Cytopathol 1995; 12(4):3038.
  • 19
    Maeda T, Adachi E, Kajiyama K, Ssugimachi K, Tsuneyashi M. Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analysis of clinicopathologic features. Hum Pathol 1995; 26:95964.
  • 20
    Ma CK, Zarbo RJ, Frierson HF, Lee MW. Comparative immunohistochemical study of primary and metastatic carcinomas of the liver. Am J Clin Pathol 1993; 99:5517.